NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, post-traumatic stress disorder, and schizophrenia. The company’s drug development focuses on modulating the N-methyl-D-aspartate (NMDA) receptor to enhance neuroplasticity. Its lead candidates include NRX-100, a preservative-free intravenous ketamine formulation; KETAFREE, a generic preservative-free ketamine formulation; and NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone. NRx is the founder and majority owner of HOPE Therapeutics, a medical services subsidiary that provides interventional psychiatry care using neuroplastic drugs, transcranial magnetic stimulation, digital therapeutics, and hyperbaric therapy. HOPE operates clinics in Florida and has acquired Dura Medical and Cohen and Associates to expand its network. The company partners with Osmind, Inc. for real-world evidence analysis and utilizes the ONE-D protocol for transcranial magnetic stimulation treatments.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage nrxpharma.com
Sector Healthcare IR page nrxpharma.com/nrx-pharmaceuticals-investigational-new-drug-ind-application-for-nrx-100-ketamine-in-the-treatment-of-acute-suicidality
Tags
central nervous system disorders, suicidal depression, post-traumatic stress disorder, ketamine, transcranial magnetic stimulation, interventional psychiatry, neuroplasticity, nmda receptor modulation, digital therapeutics, hyperbaric therapy, NeuroRx Inc., HOPE Therapeutics Inc., NRX-100, KETAFREE, NRX-101, HTX Management Company LLC, Dura Medical LLC, Cohen and Associates, Osmind Inc., ONE-D protocol, Ampa Health TMS device
Press page —

Metrics

Valuation  
Market cap $ 126.167M
Market cap (USD) $ 126.167M
P/E -6.38
PEG —
P/BV -63.53
P/S 102.99
P/OCF -5.35
P/FCF -8.94
Dividend yield —
Turnover / mcap —
Returns  
ROE 179.6%
ROI —
ROIC —
Profit margin -2,336.5%
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock —
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 82
Quality score -54.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 1.225M 0 — — — —
Net profit -28.622M -25.126M -30.15M -39.754M -93.063M -51.777M
Free cash flow -14.112M -10.637M -21.66M -39.765M -37.71M -2.267M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 2.71 2.2 0.31 1.14 11.76 —
Price performance 12m 0.23 6.21 -0.73 -0.9 — —

Filed figures

Figure Sep 2018 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — 831,390 — — — 0.00 161,000
↳ 5y CAGR -28.0%
Borrowings, current (USD) — — — — — 7.7M 9.16M — —
Borrowings, non-current (USD) — — — — — 2.82M — — —
Lease liabilities (USD) — — — — — — — — 631,000
Cash and deposits (USD) — — 877,000 1.86M 27.6M 20.1M 4.6M 1.44M 7.8M
Intangible assets (USD) — — — — — — — 0.00 925,000
Net debt (borrowings + leases - cash) (USD) — — — — — -9.53M 4.57M — —
Cash flow detail
Operating cash flow (USD) -30.00 -473,187 -792,731 -598,617 -37.7M -39.8M -21.7M -10.6M -14.1M
Purchases of property, plant and equipment (USD) — — — -2,000 -7,000 -10,000 -3,000 0.00 —
Change in receivables (cash effect) (USD) — — — -831,000 831,000 — — 0.00 48,000
Change in payables (cash effect) (USD) 1,157 465,428 71,342 339,139 -19,000 -1.61M 2.66M -5.22M 113,000
Interest paid (cash effect) (USD) — — — — — — -885,000 -374,000 0.00
Income taxes paid (cash effect) (USD) — 0.00 -170,000 0.00 — — 0.00 0.00 0.00
Share-based compensation (USD) — — — 730,000 7.79M 3.63M 387,000 486,000 228,000
Operating cash flow before change in receivables (USD) — — — -1.43M -38.5M — — -10.6M -14.2M
Free cash flow (OCF - PPE - intangibles) (USD) — — — -2.27M -37.7M -39.8M -21.7M -10.6M —
Income detail
Research and development expense (USD) — — — 10.6M 20.3M 17M 13.4M 6.2M 3.78M
↳ 5y CAGR -18.7%
Total comprehensive income (USD) — — — — — — -30.2M -25.1M —
Comprehensive income to owners (USD) — — — — — — -30.2M -25.1M —
Provision for credit losses (USD) — — — — — — — 0.00 40,000
Credit cost ratio (credit losses / average receivables) (%) — — — — — — — — 49.7%
Reported Nov 8, 2018 Mar 30, 2020 Mar 31, 2022 Mar 31, 2022 Mar 31, 2022 Nov 14, 2023 Mar 14, 2025 Mar 23, 2026 Mar 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

October 30, 2026

• Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride (BZT), a toxic antimicrobial preservative that is not Generally Recognized as Safe (GRAS) by the FDA. Current law requires preservatives and other inactive ingredients of drugs, foods, and cosmetics to be GRAS or demonstrated to be unsafe.

• Benzethonium Chloride is known to be toxic to the cells that line the body’s organs (epithelial cells) and is banned from new drugs, consumer hand cleansers, wipes, healthcare or surgical hand rubs 1,2

• Ketamine, originally formulated in 1970 is one of the last remaining sterile drugs to contain Benzethonium Chloride.

• NRx aims to return sterile, injectable drug manufacture to the United States and to end the current shortage of traditional glass-bottled ketamine through modern, high-volume “blow-fill-seal” technology, manufactured in the United States with Nephron Pharmaceuticals in West Columbia, South Carolina.

Skip to content

Release Details

NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine

October 29, 2026

PDF Version

Company to issue press release before market open; conference call to follow at 8:30 a.m. ET

WILMINGTON, Del., Oct. 29, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, today announced that it will host a conference call at 8:30 a.m. ET on Friday, October 30, 2026, to discuss a regulatory milestone for its Preservative-Free Ketamine program and next steps on the commercial launch. The Company will issue a press release with details before the market opens that morning.

A live webcast of the conference call will be available on the Company’s website at https://ir.nrxpharma.com/events. Participants who are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-717-1738 or internationally 1-646-307-1865**.**

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company has been awarded a Abbreviated New Drug Approval (ANDA) for Preservative-Free Ketamine and is seeking New Drug Approval for a presentation of intravenous ketamine (NRX-100) with approved claims for treating depression and suicidality.

In October 2026 the Defense Advanced Research Projects Agency awarded an $11.25 million contract to NRx to conduct a phase 3 trial of its oral drug NRX-101, (D-cycloserine/lurasidone) combined with Robotic Neuronavigated Transcranial Magnetic Stimulation as a one-day treatment for patients with depression. NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

Skip to content

Release Details

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine

October 19, 2026

PDF Version

  • In advance of November 10, 2026 GDUFA goal date, three commercial lots of Preservative-Free Ketamine have been successfully manufactured in compliance with “Process Validation” required under FDA “Good Manufacturing Practices” (GMP).

  • NRx has additionally received two year stability data consistent with projected room-temperature stability to three years and beyond with no need for toxic preservatives.

  • Commercially-releasable drug supply is now on hand pending ANDA approval for this drug-shortage product.

WILMINGTON, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, today announces completion of three Process Validation lots of preservative free Ketamine produced under commercial conditions in anticipation of the November 10 GDUFA (Generic Drug User Fee Amendments) Goal Date. Process Validation1 is the final step in the drug manufacturing process required to demonstrate compliance with FDA Good Manufacturing Practices (GMP).

In related developments, NRx has now completed analysis of two-year room temperature real-time stability data on preservative-free ketamine demonstrating no deterioration in purity, potency, or sterility without the need for toxic preservatives. The Company believes that these data will be consistent with a labeled shelf life of three years or longer.

“Completing Process Validation and reaching two years of room-temperature stability puts NRx in position to supply this drug-shortage product the moment the FDA approves our ANDA,” said Jonathan Javitt, MD, MPH, the Company’s Chairman and CEO. “We thank our partners at Nephron Pharmaceuticals in West Columbia, South Carolina, for helping us show that sterile, preservative-free injectables can be made in America, and we look forward to supplying American hospitals and clinics.”

About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression.

Notice Regarding Forward-Looking Statements The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

Prompts

NRX Pharmaceuticals, Inc. (ticker NRXP), listed in United States.

Company History

Date Change Detail
Mar 1, 2021 Renamed BIG ROCK PARTNERS ACQUISITION CORP. → NRX PHARMACEUTICALS, INC.

ETFs Holding NRX Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
PSIL 4.76% 740,811 $ 1.815M Nov 17, 2026